Press release
AL Amyloidosis Pipeline and Clinical Trials Assessment (2023) | Companies- Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharmaceuticals, Sorrento Therapeutics, Inc., and others
AL Amyloidosis Pipeline
The AL Amyloidosis pipeline analysis report for AL Amyloidosis emerging drugs offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the AL Amyloidosis pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, AL Amyloidosis clinical trial studies conducted for AL Amyloidosis, any obtained AL Amyloidosis NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.
To explore more information on the latest breakthroughs in the AL Amyloidosis Pipeline treatment landscape of the report, click here @ AL Amyloidosis Pipeline Outlook- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the AL Amyloidosis Pipeline Report
• DelveInsight's AL Amyloidosis Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading AL Amyloidosis Companies are working in the market include Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharma, Sorrento Therapeutics, Inc., and others.
• Promising AL Amyloidosis Pipeline Therapies in the various stages of development include CAEL-101, Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, Bendamustine, Pomalidomide, NEOD001, Siltuximab and others.
• CAEL-101 is a fibril-reactive monoclonal antibody (mAb) that is currently in Phase III clinical development for the treatment of patients with amyloid light chain ("AL") amyloidosis. The Cardiac Amyloid Reaching for Extended Survival (CARES) clinical program includes two parallel Phase III studies - one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease - and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival. CAEL-101 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and European Medicine Agency as a therapy for patients with AL amyloidosis.
• NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. The design consists of a structurally differentiated CAR-T, with the proprietary BCMA-targeting CAR, which has demonstrated reduced toxicity in NEXICART-1, supporting investigating NXC-201 as an outpatient therapy. It is currently in Phase I NEXICART-1 study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy for the treatment of patients with relapsed or refractory multiple myeloma and light chain amyloidosis (AL).
AL Amyloidosis Overview
AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from ages 50-80, although there are a few cases of people being diagnosed as early as their late 20s. About two-thirds of the patients are male. AL amyloidosis is caused by a bone marrow disorder. The bone marrow in the center of bones produces cells in the blood system, including "plasma cells." These plasma cells are the part of the immune system that makes antibodies for fighting infections.
For further information, refer to the detailed AL Amyloidosis Unmet Needs, AL Amyloidosis Market Drivers, and AL Amyloidosis Market Barriers, click here for AL Amyloidosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Emerging Drugs Profile
• CAEL-101: Caelum Biosciences
• NXC-201: Nexcella, Inc.
AL Amyloidosis Pipeline Therapeutics Assessment
There are approx. 10+ AL Amyloidosis companies which are developing the therapies for AL Amyloidosis. The companies which have their AL Amyloidosis drug candidates in the most advanced stage, i.e. phase III.
Request a sample and discover the recent advances in AL Amyloidosis Ongoing Clinical Trial Analysis and Medications, click here @ AL Amyloidosis Treatment Landscape- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the AL Amyloidosis Therapeutics Market include-
Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharma, Sorrento Therapeutics, Inc., and others.
Dive deep into rich insights for drugs for AL Amyloidosis Pipeline, click here @ AL Amyloidosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the AL Amyloidosis Pipeline Report
• Coverage- Global
• AL Amyloidosis Companies- Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharma, Sorrento Therapeutics, Inc., and others.
• AL Amyloidosis Pipeline Therapies- CAEL-101, Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, Bendamustine, Pomalidomide, NEOD001, Siltuximab and others.
• AL Amyloidosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on AL Amyloidosis Mergers and acquisitions, AL Amyloidosis Licensing Activities @ AL Amyloidosis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. AL Amyloidosis Executive Summary
3. AL Amyloidosis: Overview
4. AL Amyloidosis Pipeline Therapeutics
5. AL Amyloidosis Therapeutic Assessment
6. AL Amyloidosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CAEL-101: Caelum Biosciences
9. AL Amyloidosis Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NXC-201: Nexcella, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. LambdaMab 10B3 & 7F11: HaemaLogiX Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. AL Amyloidosis Key Companies
21. AL Amyloidosis Key Products
22. AL Amyloidosis- Unmet Needs
23. AL Amyloidosis- Market Drivers and Barriers
24. AL Amyloidosis- Future Perspectives and Conclusion
25. AL Amyloidosis Analyst Views
26. AL Amyloidosis Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Pipeline and Clinical Trials Assessment (2023) | Companies- Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharmaceuticals, Sorrento Therapeutics, Inc., and others here
News-ID: 3081415 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Amyloid
Islet Amyloid Polypeptide Market Analysis Current Landscape and Future Outlook
The global Islet Amyloid Polypeptide market is projected to reach approximately USD 255.8 million by 2033, growing at a compound annual growth rate (CAGR) of 10.1% from 2024 to 2033.
Islet Amyloid Polypeptide Market Overview
The Islet Amyloid Polypeptide market is gaining traction due to its critical role in metabolic disorders, particularly in type 2 diabetes research and treatment. Islet Amyloid Polypeptide (IAPP), also known as amylin, is closely associated with insulin…
Cerebral Amyloid Angiopathy Pipeline Landscape: 10+ Emerging Therapies Targeting …
Cerebral Amyloid Angiopathy (CAA) is a progressive cerebral small vessel disease marked by amyloid-β (Aβ) protein deposition in the walls of leptomeningeal and cortical blood vessels. Often occurring in the elderly and closely linked with Alzheimer's disease, CAA contributes significantly to cognitive impairment, spontaneous intracerebral hemorrhage, and cerebral microbleeds. Despite its high clinical burden, there are currently no approved disease-modifying therapies specifically for CAA, and diagnosis remains challenging without advanced…
Amyloid Peptides Market to Witness Astonishing Growth by 2029
Amyloid Peptides Market is anticipated to grow at a significant CAGR during the forecast period. Growing favourable investment, as well as reimbursement facilities in the developed economic countries, is one of the major factors that is expected to fuel the global amyloid peptides market during the forecast period. Moreover, a growing number of clinical trials and research activities to develop treatment and drugs for Alzheimer's are also anticipated to boost…
Amyloid Peptides Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Amyloid Peptides Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Amyloid Peptides players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyloid Peptides with respect to individual growth…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
